Frankfurt
10.06.26 | 08:10
1,752 Euro
+3,67 % +0,062
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Orexo AB: Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships | 85 | GlobeNewswire (Europe) | Uppsala, Sweden - June 9, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announced that the company is strengthening its business development efforts through the appointment of Raheleh Nassaji... ► Artikel lesen | |
| 19.05. | Orexo announces positive outcome from an in-vivo study of OX390 | 793 | PR Newswire | UPPSALA, Sweden, May 19, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole... ► Artikel lesen | |
| 19.05. | Orexo AB: Orexo announces positive outcome from an in-vivo study of OX390 | 141 | GlobeNewswire (Europe) | Uppsala, Sweden - May 19, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with... ► Artikel lesen | |
| 07.05. | Orexo AB: Report from Orexo AB's annual general meeting May 7 2026 | 311 | GlobeNewswire (Europe) | Election of the board of directors and auditorThe annual general meeting in Orexo AB (publ) on 7 May 2026 resolved, in accordance with the nomination committee's proposal, that the number of board members... ► Artikel lesen | |
| 28.04. | Orexo AB: Orexo Q1 2026 Interim Report | 128 | GlobeNewswire (Europe) | Well positioned to advance pipeline to value inflection pointsFinancial summary January - MarchTotal net revenues of SEK 5.0 m (13.2)Net earnings for the period is SEK -105.2 m (-90.6)Cash flow for... ► Artikel lesen | |
| 06.03. | Invitation & Agenda: Orexo R&D Day on March 24 | 364 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 06.03. | Orexo changes the organizational structure and management team to increase focus on development of new products | 404 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management... ► Artikel lesen | |
| 06.03. | Orexo AB: Orexo changes the organizational structure and management team to increase focus on development of new products | 192 | GlobeNewswire (Europe) | Uppsala, Sweden - March 6, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team. The changes are a result of the divestment of... ► Artikel lesen | |
| 19.02. | Orexo AB: Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs | 384 | GlobeNewswire (Europe) | The Board of Orexo AB (publ) has today decided to convert 416,417 Class C shares into ordinary shares and to subsequently convey 416,417 ordinary shares to certain participants in the long-term incentive... ► Artikel lesen | |
| 05.02. | Orexo AB: Orexo Interim Report Q4 2025, incl. Full Year Report | 384 | GlobeNewswire (Europe) | Turning a transformative deal into new opportunitiesQ4 2025 highlights›Dexcel Pharma USA aquired all rights to Zubsolv® US on December 31, at a purchase price of USD 91 m plus the value of inventory... ► Artikel lesen | |
| 22.12.25 | Orexo AB: Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv | 418 | GlobeNewswire (Europe) | · An asset purchase agreement has been signed with Dexcel Pharma USA, which will acquire the full rights to Zubsolv® in the US, at a purchase price of USD 91 million plus the value of inventory at closing... ► Artikel lesen | |
| 23.10.25 | Orexo AB: Orexo Q3 2025 Interim Report | 232 | GlobeNewswire (Europe) | Unlocking the potential of the AmorphOX® technologyQ3 2025 highlights› Total net revenues of SEK 118.7 m (136.5)› EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with... ► Artikel lesen | |
| 01.10.25 | Orexo AB: Orexo strengthens innovation and research with move to new premises | 219 | GlobeNewswire (Europe) | Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move... ► Artikel lesen | |
| 29.09.25 | Orexo AB: Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership | 440 | GlobeNewswire (Europe) | Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical... ► Artikel lesen | |
| 05.09.25 | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 1.141 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
| 29.08.25 | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 482 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen | |
| 16.07.25 | Orexo AB: Orexo Q2 2025 Interim Report | 394 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 2,884 | -1,70 % | Aurora Cannabis Q4 earnings on deck: Here's what to expect | ||
| ABBVIE | 195,60 | +0,33 % | Drei Qualitätswerte im Fokus: Was der "Quant Growth And Income"-Ansatz jetzt über Microsoft, Visa und AbbVie verrät | Microsoft, Visa und AbbVie stehen im Zentrum eines quantitativen Wachstums- und Einkommensansatzes, den Seeking Alpha aktuell transparent macht. Der Einblick in das "Quant Growth And Income"-Portfolio... ► Artikel lesen | |
| TILRAY BRANDS | 4,380 | +0,57 % | Tilray Brands, Inc.: Tilray Medical Deutschland bringt ARX auf den Markt, eine neue Premium-Marke für medizinisches Cannabis aus deutschem Anbau | Die neue Marke vereint bewährte Genetik, deutsches Anbauknow-how und strenge Qualitätsstandards, um Patienten und medizinisches Fachpersonal in ganz Deutschland zu unterstützenNEUMÜNSTER, Deutschland... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 48,275 | +0,19 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| TEVA | 29,400 | +1,03 % | Teva Pharmaceutical Industries Ltd: Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy | Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug... ► Artikel lesen | |
| BAUSCH HEALTH | 4,614 | +3,69 % | Bausch Health Companies Inc: Bausch Health signs LOI for schizophrenia coverage | ||
| BIONANO GENOMICS | 1,165 | +0,43 % | Bionano Genomics, Inc. - 8-K, Current Report | ||
| OPKO HEALTH | 1,220 | -3,17 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| JAGUAR HEALTH | 2,700 | -1,82 % | Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders | Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jaguar... ► Artikel lesen | |
| KEENOVA THERAPEUTICS | - | - | Keenova Therapeutics: Keenova Reports First Quarter 2026 Financial Results | Strong First-Quarter Performance Driven by Acthar® Gel1 and XIAFLEX®2
Pipeline Development, Synergy Plan Remain on Track
Reaffirms 2026 Net Sales Guidance of $1.94... ► Artikel lesen | |
| AVALO THERAPEUTICS | 11,180 | -1,41 % | Avalo Therapeutics, Inc. - 8-K, Current Report | ||
| BAYER | 35,370 | -0,34 % | Iran-Krieg: DAX schwächer - Broadcom, Crowdstrike, Hochtief, Porsche SE, RWE, Bayer, SAP im ... | Der DAX hat am Mittwoch deutlich Federn lassen müssen. Aus dem Handel ging er am Ende mit einem Minus von 1,3 Prozent bei 24.795,94 Zählern. Und auch der Start in den Donnerstag sieht schwächer aus.... ► Artikel lesen | |
| MERCK KGAA | 136,45 | -1,23 % | EQS-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Merck KGaA
Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08.06.2026 / 16:57 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| NOVO NORDISK | 37,800 | +5,62 % | Aktien im Fokus - Nel ASA: Eine Falle? - EverYield, Indus, Mutares, Novo Nordisk und Suss MicroTec | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 61,57 | +0,02 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.